Lambert-Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation.
The Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disease that can be transmitted from human to mouse with immunoglobulin G (IgG). Electrophysiological studies indicate that LEMS IgG acts on presynaptic voltage-sensitive calcium channels, probably reducing their number, and freeze-fracture electron microscopy demonstrates that LEMS IgG has an effect on the presynaptic active zone particles, which represent putative voltage-sensitive calcium channels. The active zone particles, normally arranged in double parallel rows, move closer together, form clusters, and are reduced in number. The morphological data suggest modulation of the active zone particles crosslinked by LEMS IgG. If this were the case, then only divalent LEMS IgG and F(ab')2 should alter the deployment of active zone particles and monovalent Fab should be without effect. To test this hypothesis, mouse diaphragms were exposed to control and LEMS IgG and IgG fragments in organ culture for 24 hours and then studied by quantitative freeze-fracture electron microscopy. Divalent LEMS IgG and F(ab')2 aggregated and depleted the active zone particles, whereas monovalent Fab had no effect. The findings reconfirm that the active zone particles are targets of LEMS IgG and are direct evidence for modulation of the particles by LEMS IgG. The findings are in harmony with parallel electrophysiological studies of the effects of LEMS IgG fragments on transmitter release in the same diaphragm muscles (Lang et al, J Physiol 1987;390:173P).
Nagel
A
A
Department of Neurology and Neuromuscular Research Laboratory, Mayo Clinic, Rochester, MN 55905.
Engel
A G
AG
Lang
B
B
Newsom-Davis
J
J
Fukuoka
T
T
D000818:Animals; D001327:Autoimmune Diseases / Q000276:immunology*; D015220:Calcium Channels / Q000187:drug effects* / Q000502:physiology; D005614:Freeze Fracturing; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology; D007143:Immunoglobulin Heavy Chains / Q000494:pharmacology*; D007142:Immunoglobulin gamma-Chains / Q000494:pharmacology*; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D009046:Motor Neurons / Q000276:immunology*; D009468:Neuromuscular Diseases / Q000276:immunology*; D013569:Synapses / Q000187:drug effects* / Q000502:physiology / Q000648:ultrastructure; D013577:Syndrome
D015220:Calcium Channels; D007140:Immunoglobulin Fab Fragments; D007143:Immunoglobulin Heavy Chains; D007142:Immunoglobulin gamma-Chains